RVX_logo_RGB.jpg
Resverlogix Announces Corporate Update Webcast and Conference Call
December 13, 2021 06:00 ET | Resverlogix Corp
CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that they will be hosting a corporate update webcast and conference call on Thursday,...
RVX_logo_RGB.jpg
Resverlogix 與阿拉伯非洲經濟最高委員會達成合作協議,以支援為 2019 冠狀病毒病患者開發 Apabetalone
November 04, 2021 08:05 ET | Resverlogix Corp
亞伯達省卡加利, Nov. 04, 2021 (GLOBE NEWSWIRE) -- 表觀遺傳學或基因調控領域的世界領導者 Resverlogix Corp.(以下簡稱為「Resverlogix」或「公司」)(TSX: RVX) 今日欣然宣佈,其已與阿拉伯非洲經濟最高委員會達成合作協議,表示有興趣提供必要的投資和合作夥伴關係,以支援 Resverlogix 的一流藥物 Apabetalone...
RVX_logo_RGB.jpg
Resverlogix与阿拉伯-非洲经济最高委员会签订合作协议,以支持为新冠肺炎患者开发Apabetalone
November 04, 2021 08:05 ET | Resverlogix Corp
艾伯塔省卡尔加里, Nov. 04, 2021 (GLOBE NEWSWIRE) -- 全球表观遗传学或基因调控领导者Resverlogix...
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
November 03, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
November 01, 2021 08:30 ET | Resverlogix Corp
CALGARY, Alberta, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today...
RVX_logo_RGB.jpg
Resverlogix与摩洛哥王国卫生部积极讨论启动采用同类首创药物Apabetalone实施的新冠肺炎临床研究
November 01, 2021 08:30 ET | Resverlogix Corp
艾伯塔省卡尔加里, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 作為表觀遺傳學或基因調節的全球領導者的 Resverlogix 集團(「Resverlogix」或「公司」) (TSX: RVX) 今天欣然宣佈,它正在與摩洛哥王國衛生部積極討論,可在其醫院中使用一流藥物 Apabetalone 進行第 2 期 COVID-19 臨床研究。 Resverlogix...
RVX_logo_RGB.jpg
Resverlogix 與摩洛哥王國衛生部進行積極討論,以啟動 COVID-19 臨床研究以及頂尖藥物 Apabetalone
November 01, 2021 08:30 ET | Resverlogix Corp
亞伯達省卡加利, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 作為表觀遺傳學或基因調節的全球領導者的 Resverlogix 集團(「Resverlogix」或「公司」) (TSX: RVX) 今天欣然宣佈,它正在與摩洛哥王國衛生部積極討論,可在其醫院中使用一流藥物 Apabetalone 進行第 2 期 COVID-19 臨床研究。 Resverlogix...
RVX_logo_RGB.jpg
Resverlogix to Participate in Leading Scientific Conferences
October 29, 2021 08:30 ET | Resverlogix Corp
Presentations will Showcase Research by Resverlogix Scientists, Advancing our Understanding of Epigenetics in Chronic Diseases CALGARY, Alberta, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp....
RVX_logo_RGB.jpg
Resverlogix to Present at Upcoming Conferences
October 13, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and...
RVX_logo_RGB.jpg
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
October 12, 2021 16:35 ET | Resverlogix Corp
CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the...